scFv(EPCAM)-CD3zeta CAR-T Lentivirus

scFv(EPCAM)-CD3zeta CAR-T lentivirus is a highly efficient and stable gene delivery system designed to modify T cells for targeted immunotherapy. This lentiviral vector platform is characterized by its ability to directly integrate chimeric antigen receptor (CAR) transgenes into the host T cell genome. Unlike transient expression systems, this stable integration ensures sustained expression of the anti-EpCAM CAR and its delivery to all progeny cells during T cell expansion, which is crucial for maintaining durable therapeutic effects. One of the significant advantages of using a lentiviral delivery mechanism is its high transduction efficiency in primary human lymphocytes. This system employs a third-generation self-inactivated (SIN) lentiviral design, significantly reducing the risk of generating replicating lentiviruses (RCLs) and minimizing the possibility of insertional mutations, thereby improving safety. Furthermore, these lentiviral particles are typically pseudotyped with the VSV-G envelope protein, giving them broad tropism and the robustness required to withstand the physical stresses during transduction.

The application of scFv(EPCAM)-CD3zeta CAR-T lentivirus is primarily focused on advancing adoptive cell therapy for solid tumors. Epithelial cell adhesion molecule (EpCAM) is a well-known tumor-associated antigen overexpressed in a variety of cancers, including colon, lung, breast, and pancreatic cancer, making it a key target for oncology research. In a laboratory setting, this product is used to evaluate the fundamental mechanisms of T cell signaling and the potency of “Signal 1” (the primary activation signal) in the absence of secondary co-stimulatory domains. It serves as an important benchmark or control for comparative studies with second- and third-generation CAR designs containing 4-1BB or CD28 domains. In addition to basic signaling studies, these lentiviral particles can be used to perform rigorous in vitro cytotoxicity assays to measure the ability of engineered T cells to selectively lyse EpCAM-positive tumor cells. Furthermore, they are crucial for establishing in vivo proof-of-concept in animal models, enabling researchers to investigate the biodistribution, tumor invasion, and antitumor efficacy of EpCAM-targeted CAR-T cells in complex physiological settings.